Clover Biopharmaceuticals Inc., of Chengdu, China, said it completed a $43 million (¥304 million) series B financing led by Delos Capital and Lapam Capital, with participation from Betta Capital, Sichuan Health Care Industry Fund, Beijing Zhongguancun VC and Jinlong Group. The proceeds will support the continued clinical development of the company’s biological candidates, operations of its new commercial-scale cGMP biomanufacturing facility, and expansion of its preclinical R&D pipeline utilizing its Trimer-Tag technology platform.
Kuros Biosciences Ltd., of Schlieren, Switzerland, said it obtained a binding order from Optiverder BV for 2.81 million offered shares at CHF1.95 each for a total of CHF5.49 million (US$5.53 million). As a result, the minimum gross proceeds, set at CHF4 million, required to complete the offering has been surpassed.
Humanigen Inc., of Burlingame, Calif., said it has terminated the process of exploring a potential rights offering. It has initiated other capital raising alternatives better suited to the existing capital structure.
Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it closed a public offering of 446,577 shares of common stock at $3.50 each for net proceeds of approximately $1.4 million, which will be used for general working capital, especially to fund marketing and product development efforts. The company’s shares (NASDAQ:SNOA) closed Monday at $3.95, up 2 cents.
Vigeneron GmbH, of Munich, Germany, said it closed its series A financing round led by Wuxi Apptec and Sequoia Capital China. The proceeds will support the acceleration of its viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. The company’s vgAAV vector platform, based on engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers to allow the vectors to target a broad spectrum of cell types in the retina and potentially other tissues, such as central nervous system tissue. For larger genes (>5kb) the company has developed a Revert vector platform that packs split genes into individual vgAAV vectors and generates a full-length protein via mRNA trans-splicing.